New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
04:55 EDTXLRN, XLRN, XLRN, AGIO, AGIO, AGIO, ALKS, ALKS, ALKS, ALNY, ALNY, ALNY, ARIA, ARIA, ARIA, EPZM, EPZM, EPZM, IMGN, IMGN, IMGN, TSRO, TSRO, TSROLeerink to hold a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 14-16.
News For XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO From The Last 14 Days
Check below for free stories on XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
16:13 EDTTSROTESARO names Mary Lynne Hedley COO
TESARO announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
16:13 EDTTSROTESARO reports Q2 EPS ($1.03), consensus (87c)
Subscribe for More Information
July 23, 2014
18:34 EDTARIAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Fortinet (FTNT), up 7.8%... Hanesbrands (HBI), up 5.4%... 8x8 (EGHT), up 5.1%... Infinera (INFN), up 4.9%... Facebook (FB), reverses and is now trading up 5.1% following second quarter earnings conference call. NOTABLE: Twitter (TWTR), up 1.7%, LinkedIn (LNKD), up marginally, and Yelp (YELP), up 1.6% after Facebook reports second quarter results. ALSO HIGHER: Spectranetics (SPNC), up 7.1% after receiving FDA clearance for atherectomy products, Turbo-Tandem and Turbo Elite... Ariad Pharmaceuticals (ARIA), up 7.1%... Jamba (JMBA), up 3.8% after Engaged Capital reports stake in the company and announced that they had discussions with management. DOWN AFTER EARNINGS: AT&T (T), down 1.2%... Angie's List (ANGI), down 16.4%... Tripadvisor (TRIP), down 11.5%... Orchids Paper (TIS), down 7.4%... Cirrus Logic (CRUS), down 6.6%... Cliffs Natural (CLF), down 1.2%... Teradyne (TER), down 4%. ALSO LOWER: Kandi Technologies (KNDI), down 3.8% after being mentioned negatively in a Seeking Alpha blog post.
13:59 EDTARIAARIAD rises 11.8% to $5.70
July 22, 2014
08:03 EDTALNYAlnylam receives USPTO Notice of Allowance for Manoharan ’478 patent
Subscribe for More Information
07:22 EDTALNYAlnylam to hold a webinar
Subscribe for More Information
July 17, 2014
07:05 EDTALKSAlkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS
Subscribe for More Information
July 15, 2014
10:28 EDTIMGNHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI
10:08 EDTIMGNImmunoGen receives orphan status for ovarian cancer treatment
Subscribe for More Information
10:00 EDTEPZMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:25 EDTALNYAlnylam to hold a roundtable
Subscribe for More Information
07:08 EDTEPZMEpizyme initiated with a Buy at H.C. Wainwright
Target $40.
July 14, 2014
07:37 EDTARIAARIAD announces continuation of Iclusig review under Article 20 procedure
ARIAD Pharmaceuticals announced that the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has provided the company with a request for limited additional information regarding Iclusig as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD’s response and input from the agency’s Scientific Advisory Group, the company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use at its meeting in October. As we finalize our recommendations on dose modifications of Iclusig and response monitoring of patients, we will work closely with the European regulatory agency and its expert advisors so that CML patients and their treating physicians have the best guidance available supporting the appropriate use of Iclusig,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. In March ARIAD submitted responses to initial questions outlined by the PRAC as part of the Article 20 process, which was initiated in December of last year, and responses to a second set of questions were submitted to the PRAC in June.
July 11, 2014
07:38 EDTALKSHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use